Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1951 1
1952 2
1956 1
1959 2
1960 2
1965 1
1966 1
1967 1
1969 1
1971 3
1972 3
1973 2
1974 1
1976 2
1977 2
1979 1
1980 4
1982 1
1983 3
1984 1
1985 4
1986 1
1987 2
1988 1
1990 1
1991 5
1992 7
1993 4
1994 6
1995 4
1996 6
1997 2
1998 2
1999 4
2000 6
2001 3
2002 2
2003 3
2004 10
2005 11
2006 17
2007 15
2008 15
2009 12
2010 8
2011 15
2012 14
2013 19
2014 17
2015 15
2016 15
2017 26
2018 26
2019 24
2020 26
2021 25
2022 40
2023 36
2024 29

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

473 results

Results by year

Filters applied: . Clear all
Page 1
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, Cruz FM, Wyrwicz L, Stroyakovskiy D, Pápai Z, Poureau PG, Liposits G, Cremolini C, Bondarenko I, Modest DP, Benhadji KA, Amellal N, Leger C, Vidot L, Tabernero J; SUNLIGHT Investigators. Prager GW, et al. N Engl J Med. 2023 May 4;388(18):1657-1667. doi: 10.1056/NEJMoa2214963. N Engl J Med. 2023. PMID: 37133585 Clinical Trial.
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Paz-Ares L, et al. Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4. Lancet. 2019. PMID: 31590988 Clinical Trial.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Rha SY, et al. Lancet Oncol. 2023 Nov;24(11):1181-1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875143 Clinical Trial.
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T; KEYNOTE-426 Investigators. Rini BI, et al. N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16. N Engl J Med. 2019. PMID: 30779529 Clinical Trial.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
Scenario user guide.
Horvath Z, Quick KK. Horvath Z, et al. J Dent Educ. 2022 Mar;86(3):372-376. doi: 10.1002/jdd.12840. Epub 2021 Dec 9. J Dent Educ. 2022. PMID: 34888875 No abstract available.
Levél az emlőrák felismerésétől az emlőrákos betegek rehabilitációjáig tartó folyamat javításának érdekében.
A III. Emlőrák Konszenzuskonferencia munkacsoportjainak és szervezőbizottságának vezetői:; Forrai G, Lázár G, Cserni G, Polgár C, Horváth Z, Kahán Z, Kásler M, Svébis M. A III. Emlőrák Konszenzuskonferencia munkacsoportjainak és szervezőbizottságának vezetői:, et al. Among authors: horvath z. Magy Seb. 2016 Dec;69(4):203-207. doi: 10.1556/1046.69.2016.4.11. Magy Seb. 2016. PMID: 27991026 Hungarian. No abstract available.
Scenario I: Opportunity lost.
Quick KK, Horvath Z, Danciu TE, Dehghan M, Godley LW, Kabani FA. Quick KK, et al. Among authors: horvath z. J Dent Educ. 2022 Mar;86(3):352-355. doi: 10.1002/jdd.12839. Epub 2021 Dec 9. J Dent Educ. 2022. PMID: 34888868 No abstract available.
The spread of the J Project.
Horváth Z, Rezaei N, Reisli I, Tuzankina I, Otarbayev N, Popandopulo P, Maródi L. Horváth Z, et al. J Clin Immunol. 2013 Aug;33(6):1037-42. doi: 10.1007/s10875-013-9905-2. Epub 2013 May 19. J Clin Immunol. 2013. PMID: 23686437 Review.
473 results